Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation With Bevacizumab for Advanced Solid Tumor.

Next Previous
Trial Profile

Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation With Bevacizumab for Advanced Solid Tumor.

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 04 Feb 2013

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Antithymocyte globulin; Fludarabine; Melphalan
  • Indications Advanced breast cancer; Ovarian cancer; Renal cancer
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 03 Nov 2011 Planned end date changed from 1 Feb 2012 to 1 Oct 2011 as reported by ClinicalTrials.gov.
  • 03 Nov 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
  • 06 Nov 2010 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top